FCY-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive post-transplant lymphoproliferative disorder

Zimmermann, Heiner, Weiland, Theresa, Nourse, Jamie P., Gandhi, Maher K., Reinke, Petra, Neuhaus, Ruth, Karbasiyan, Mohsen, Gärtner, Barbara, Anagnostopoulos, Ioannis, Riess, Hanno, Trappe, Ralf and Oertel, Stephan (2014) FCY-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive post-transplant lymphoproliferative disorder. Journal of Immunology Research, 264723 1-6. doi:10.1155/2014/264723


Author Zimmermann, Heiner
Weiland, Theresa
Nourse, Jamie P.
Gandhi, Maher K.
Reinke, Petra
Neuhaus, Ruth
Karbasiyan, Mohsen
Gärtner, Barbara
Anagnostopoulos, Ioannis
Riess, Hanno
Trappe, Ralf
Oertel, Stephan
Title FCY-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive post-transplant lymphoproliferative disorder
Journal name Journal of Immunology Research   Check publisher's open access policy
ISSN 2314-8861
2314-7156
Publication date 2014-02-10
Year available 2014
Sub-type Article (original research)
DOI 10.1155/2014/264723
Open Access Status DOI
Volume 264723
Start page 1
End page 6
Total pages 6
Place of publication New York, United States
Publisher Hindawi Publishing Corporation
Collection year 2015
Language eng
Abstract We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy. Previous reports had indicated that the lower affinity F allele affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and is linked to inferior outcome of rituximab monotherapy in B cell malignancies. 25 patients with PTLD after solid organ transplantation were included in this analysis. They had received 4 weekly doses of rituximab as part of two clinical trials, which had a rituximab monotherapy induction regimen in common. 16/25 patients received further treatment with CHOP-21 after rituximab monotherapy (PTLD-1, NCT01458548). The FCGR3A status was correlated to the response after 4 cycles of rituximab monotherapy. Response to rituximab monotherapy was not affected by F carrier status. This is in contrast to previous findings in B cell malignancies where investigators found a predictive impact of FCGR3A status on outcome to rituximab monotherapy. One explanation for this finding could be that ADCC is impaired in transplant recipients receiving immunosuppression. These results suggest that carrying a FCRG3A F allele does not negatively affect rituximab therapy in immunosuppressed patients.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 16 Mar 2015, 09:10:09 EST by Maher Gandhi on behalf of UQ Diamantina Institute